IL154736A0 - Acid-sensitive compounds, preparation and uses thereof - Google Patents
Acid-sensitive compounds, preparation and uses thereofInfo
- Publication number
- IL154736A0 IL154736A0 IL15473601A IL15473601A IL154736A0 IL 154736 A0 IL154736 A0 IL 154736A0 IL 15473601 A IL15473601 A IL 15473601A IL 15473601 A IL15473601 A IL 15473601A IL 154736 A0 IL154736 A0 IL 154736A0
- Authority
- IL
- Israel
- Prior art keywords
- acid
- sensitive
- compounds
- acidic
- biologically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0011278A FR2813605B1 (fr) | 2000-09-05 | 2000-09-05 | Composes acidosensibles, leur preparation et utilisations |
US23911600P | 2000-10-11 | 2000-10-11 | |
PCT/FR2001/002725 WO2002020510A1 (fr) | 2000-09-05 | 2001-09-03 | Composes acidosensibles, leur preparation et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154736A0 true IL154736A0 (en) | 2003-10-31 |
Family
ID=26212598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15473601A IL154736A0 (en) | 2000-09-05 | 2001-09-03 | Acid-sensitive compounds, preparation and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050085426A1 (xx) |
EP (1) | EP1317439B1 (xx) |
JP (1) | JP2004508364A (xx) |
KR (1) | KR20030040441A (xx) |
CN (1) | CN1452617A (xx) |
AT (1) | ATE312088T1 (xx) |
AU (1) | AU2001287801A1 (xx) |
CA (1) | CA2421179A1 (xx) |
DE (1) | DE60115667T2 (xx) |
HU (1) | HUP0303379A3 (xx) |
IL (1) | IL154736A0 (xx) |
MX (1) | MXPA03001876A (xx) |
WO (1) | WO2002020510A1 (xx) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004111077A1 (en) | 2003-06-18 | 2004-12-23 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
FR2925491B1 (fr) * | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules |
KR101014246B1 (ko) | 2008-07-03 | 2011-02-16 | 포항공과대학교 산학협력단 | 페하 민감성 금속 나노 입자 및 이의 제조 방법. |
GB201307438D0 (en) * | 2013-04-25 | 2013-06-05 | Airbus Uk Ltd | Fuel Additive |
KR101725240B1 (ko) | 2015-03-24 | 2017-04-11 | 부산대학교 산학협력단 | UV-광 반응성 및 pH 반응성을 갖는 이중 자극 반응성 코어-쉘 자성나노입자 및 이를 포함하는 약물 전달체 |
EP3095790A1 (en) | 2015-05-22 | 2016-11-23 | Universite De Bordeaux | Nucleoside-lipid compounds with ph-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent |
US10822323B2 (en) * | 2018-02-26 | 2020-11-03 | Waters Technologies Corporation | Acid labile surfactants |
CN116656706A (zh) * | 2023-04-18 | 2023-08-29 | 河南中医药大学第一附属医院 | 一种酸敏融合蛋白重组质粒及其构建、应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4406686A (en) * | 1981-07-24 | 1983-09-27 | Stauffer Chemical Company | Haloalkylaminomethyldioxolane herbicide antidotes |
FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
-
2001
- 2001-09-03 US US10/129,262 patent/US20050085426A1/en not_active Abandoned
- 2001-09-03 HU HU0303379A patent/HUP0303379A3/hu unknown
- 2001-09-03 JP JP2002525131A patent/JP2004508364A/ja not_active Withdrawn
- 2001-09-03 KR KR10-2003-7003237A patent/KR20030040441A/ko not_active Application Discontinuation
- 2001-09-03 MX MXPA03001876A patent/MXPA03001876A/es unknown
- 2001-09-03 AU AU2001287801A patent/AU2001287801A1/en not_active Abandoned
- 2001-09-03 IL IL15473601A patent/IL154736A0/xx unknown
- 2001-09-03 EP EP01967418A patent/EP1317439B1/fr not_active Expired - Lifetime
- 2001-09-03 AT AT01967418T patent/ATE312088T1/de not_active IP Right Cessation
- 2001-09-03 CN CN01815200A patent/CN1452617A/zh active Pending
- 2001-09-03 CA CA002421179A patent/CA2421179A1/en not_active Abandoned
- 2001-09-03 WO PCT/FR2001/002725 patent/WO2002020510A1/fr active IP Right Grant
- 2001-09-03 DE DE60115667T patent/DE60115667T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1317439A1 (fr) | 2003-06-11 |
AU2001287801A1 (en) | 2002-03-22 |
KR20030040441A (ko) | 2003-05-22 |
WO2002020510A1 (fr) | 2002-03-14 |
HUP0303379A2 (hu) | 2004-01-28 |
MXPA03001876A (es) | 2004-09-10 |
US20050085426A1 (en) | 2005-04-21 |
DE60115667T2 (de) | 2006-08-24 |
EP1317439B1 (fr) | 2005-12-07 |
CA2421179A1 (en) | 2002-03-14 |
JP2004508364A (ja) | 2004-03-18 |
CN1452617A (zh) | 2003-10-29 |
DE60115667D1 (de) | 2006-01-12 |
HUP0303379A3 (en) | 2004-03-01 |
ATE312088T1 (de) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Metal-organic frameworks for stimuli-responsive drug delivery | |
Rojas et al. | Metal organic frameworks based on bioactive components | |
Kim et al. | Glutathione‐induced intracellular release of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers | |
BR0009176A (pt) | Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular | |
AR111695A2 (es) | Suspensiones acuosas estabilizadas para administración parenteral | |
AR043863A1 (es) | Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines | |
RU2008112146A (ru) | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью | |
NZ506241A (en) | Solid cyclodextrin flavor delivery systems | |
HK1064295A1 (en) | Medical aerosol formulations | |
CN101797387B (zh) | 一种可携带基因和药物的磁性靶向载体及其制备方法和应用 | |
BR0008711A (pt) | Encapsulação de complexos bioativos em lipossomas | |
He et al. | One-pot self-assembly of mesoporous silica nanoparticle-based pH-responsive anti-cancer nano drug delivery system | |
WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
NI200600146A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
CN109833329A (zh) | 一种透明质酸-多孔纳米硒复合物及其制备方法与应用 | |
IL154736A0 (en) | Acid-sensitive compounds, preparation and uses thereof | |
Tazina et al. | Specific features of drug encapsulation in liposomes (A review) | |
ES2855985T3 (es) | Agente terapéutico para su uso en el tratamiento de infecciones | |
Lee et al. | A mesoporous nanocontainer gated by a stimuli-responsive peptide for selective triggering of intracellular drug release | |
Wang et al. | Carborane based mesoporous nanoparticles as a potential agent for BNCT | |
CN102604082B (zh) | 顺铂配合物及其制备方法 | |
ITMI20022549A1 (it) | Composizione quaternaria comprendente come sostanza attiva la propolis. | |
RU2693410C1 (ru) | Композиция с супрамолекулярной структурой коллоидной смеси комплексных соединений наноструктурных частиц серебра или гидрозоля катионов серебра в водном или в водно-органическом растворе, обладающая антимикробным и антитоксическим действием (варианты), и способ ее получения | |
EP1634585A4 (en) | MEDICINAL PRODUCTS CONTAINING DELAYED MICROTEIL, PROCESS FOR ITS PREPARATION AND MICROPARTICLE CONTAINING PREPARATION | |
Hosny | Anticancer and antimicrobial MOFs and their derived materials |